New combo for tough melanoma shows promise but trial halted early
Disease control
Terminated
This study tested a combination of two drugs (duvelisib and nivolumab) in 13 people with advanced melanoma that had stopped responding to standard immunotherapy. The goal was to find the best dose and see if the combination could shrink tumors or slow the disease. The trial was t…
Phase: PHASE1, PHASE2 • Sponsor: John Kirkwood • Aim: Disease control
Last updated May 17, 2026 01:03 UTC